PORKEROpen the app

House bill · 119th Congress · Latest step: Introduced

Next GEN Act of 2026

H.R. 8857Introduced May 15, 2026Policy area: Health

Official title: To amend title XI of the Social Security Act to adjust which engineered cyclic peptides are qualifying single source drugs for purposes of the Drug Price Negotiation Program.

Sponsor: Rep. Joseph Morelle D-NY
Open in Bill Explorer →

Where it went

Latest action: May 15, 2026 — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Cost and committee reports

Official records Congress.gov attaches to H.R. 8857.

Congress.gov’s record for this bill does not list a CBO cost estimate or a committee report (as of September 19, 2026). Not every bill gets one.

From the Congress.gov bill record for H.R. 8857, last updated September 19, 2026. PORKER’s copy was retrieved September 24, 2026 and is refreshed nightly. Open “Evidence” on any line for the record, field and file fingerprint.

Vote results

No recorded roll-call votes on this bill in PORKER’s records (voice votes and unanimous consent are not roll calls; roll-call records start in 2011).

Cosponsors

4 cosponsors — 2 Republicans, 2 Democrats

2 of 4 cosponsors (50%) are from the other party.

Donald Davis (D-NC), Josh Gottheimer (D-NJ), Thomas Kean (R-NJ), August Pfluger (R-TX).

More from the sponsor

Other 119th Congress bills sponsored by Rep. Joseph Morelle.

Sponsor’s state and district

New York in Congress · NY-25 district

Open in Bill Explorer →

Data as of Sep 24, 2026 · bill record checked by PORKER from Congress.gov · votes from Senate.gov and the House Clerk. PORKER is non-partisan.